#Type 2 diabetes

T2D pharmacotherapy, glycaemic control, guideline shifts.

Australian sales and PBS data show rapid GLP-1 medicine growth, with nearly half of estimated use accessed privately in the final study year.

A retrospective cohort linked higher-dose oral semaglutide and SGLT-2 inhibitor use with improved arterial stiffness, without proving causation.

FLOW established kidney-outcome evidence for semaglutide in diabetic CKD. A translational review explains why SGLT2 combination trials are next.

A Canadian analysis estimated how far GLP-1 receptor agonist prices would need to fall to become cost-effective.

A 2026 meta-analysis linked GLP-1 therapies to changes in selected inflammation and metabolic biomarkers in type 2 diabetes.

A letter on tirzepatide ocular outcomes has no public abstract. The underlying cohort found associations, not proof of eye protection.

A matched MASLD cohort linked tirzepatide to fewer deaths and liver events than SGLT2 inhibitors, but it cannot prove superiority.

REDEFINE 3 has published its CagriSema trial design and baseline cohort, but cardiovascular outcome results remain pending.

A 2026 meta-analysis found no significant MACE difference versus GLP-1 drugs, with high heterogeneity and mostly observational evidence.

SURPASS-EARLY found larger two-year HbA1c and weight reductions with tirzepatide than flexible conventional care in early type 2 diabetes.

A 2026 review links GLP-1 drugs to possible ocular-surface repair and changes around the eye, but human evidence remains small and observational.

A 2026 systematic review links pediatric GLP-1 medicines with lower BMI or HbA1c, while highlighting gastrointestinal effects and long-term gaps.